Characterization of the EGF receptor status in penile cancer : RRRRRetrospective analysis of the course of the disease in 45 patients;Charakterisierung des EGF-Rezeptorstatus beim Peniskarzinom : Retrospektive Auswertung der Krankheitsverläufe von 45 Patienten

Urologe - Ausgabe A

Volumn 48, Issue 12, 2009, Pages 1483-1489

  Borgermann C ^a   Schmitz, K J ^a   Sommer, S ^b   Rubben H ^a   Krege, S ^c  

^a UNIVERSITY HOSPITAL ESSEN   (Germany)

^b Anästhesiologische Universitätsklinik   (Germany)

^c Krankenhaus Maria Hilf   (Germany)

Author keywords

Chemotherapy; EGF receptor expression; Lymphadenectomy; Penile cancer

Indexed keywords

ANTINEOPLASTIC AGENT; BLEOMYCIN; CARBOPLATIN; CISPLATIN; EPIDERMAL GROWTH FACTOR RECEPTOR; FLUOROURACIL; METHOTREXATE; PACLITAXEL; VINBLASTINE;

ADJUVANT THERAPY; ADULT; AGED; ARTICLE; CANCER MORTALITY; CANCER PATIENT; CANCER RECURRENCE; CANCER SURGERY; CLINICAL ARTICLE; CONTROLLED STUDY; DIAGNOSTIC TEST; DISEASE COURSE; DISEASE FREE SURVIVAL; GENE EXPRESSION; HISTOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; LYMPHADENECTOMY; MALE; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PATHOLOGY; PENIS CANCER; PRIMARY TUMOR; PROSTATECTOMY; RETROSPECTIVE STUDY; RISK FACTOR; SURGICAL TECHNIQUE; SURVIVAL RATE; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, SQUAMOUS CELL; HUMANS; MALE; MIDDLE AGED; NEOPLASM PROTEINS; PENILE NEOPLASMS; RECEPTOR, EPIDERMAL GROWTH FACTOR; REPRODUCIBILITY OF RESULTS; RETROSPECTIVE STUDIES; SENSITIVITY AND SPECIFICITY; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT;

EID: 74249096161     PISSN: 03402592     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00120-009-2101-6     Document Type: Article

References (30)

1. Ang KK, Berkey BA, Tu X et al (2002) Impact of epidermal growth factor receptor expression on survival and pattern of relapse in patients with advanced head and neck carcinoma. Cancer Res 62:7350-7356
2. Bonner JA, Harari PM, Giralt J et al (2006) Radiotherapy plus cetuximab in sqamous-cell carcinoma of the head and neck. N Engl J Med 354:567-578
3. Burtness B, Goldwasser MA, Flood W et al (2005) Phase III randomized trial of cisplatin plus placebo compared with cisplatin plus cetuximab in metastatic/ recurrent head and neck cancer: an Eastern Cooperative Oncology Group study. J Clin Oncol 23:8646-8654
4. Cohen EE, Rosen F, Stadler WM et al (2003) Phase II trial of ZD1839 in recurrent or metastatic squamous cell carcinoma of the head and neck. J Clin Oncol 21:1980-1987
5. Cohen EE, Davis DW, Karrison DG et al (2009) Erlotinib and bevacizumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck: a phase I/II study. Lancet 10:247-257
6. Corral DA, Sella A, Pettaway CA et al (1998) Combination chemotherapy for metastatic or locally advanced genitourinary squamous cell carcinoma: a phase II study of methotrexate, cisplatin and bleomycin. J Urol 160:1770-1774
7. Culkin DJ, Beer TM (2003) Advanced penile carcinoma. J Urol 170:359-365
8. Grandis JR, Melhem MF, Gooding WE et al (1998) Levels of TFG-alpha and EGFR protein in head and neck squamous cell carcinoma and patient survival. J Natl Cancer Inst 90:824-832
9. Heidenreich A, Th?er D, Pfister D (2008) Der Stellenwert der Targeted-Therapie beim Peniskarzinom. Urologe A 47:1320-1327
10. Herbst RS, Arquette M, Shin DM (2005) Phase II multicenter study of the epidermal growth factor receptor antibody cetuximab and cisplatin for recurrent and refractory squamous cell carcinoma of the head and neck. J Clin Oncol 23:5578-5587
11. Herbst RS, Fukuoka M, Baselga J (2004) Gefitinib ? a novel targeted approach to treating cancer. Nat Rev Cancer 4:956-965
12. Horenblas S, van Tinteren H (1994) Squamous cell carcinoma of the penis. IV Prognostic factors of survival: Analysis of tumor, nodes and metastasis classification system. J Urol 151:1239-1243
13. Hussein AM, Benedetto P, Sridhar KS (1990) Chemotherapy with cisplatin and 5-Fluorouracil for penile and urethral squamous cell carcinoma. Cancer 65:433-438
14. Kirby AM, A?Hern RP, D?Ambrosio C et al (2006) Gefitinib (ZD1839, Iressa) as palliative treatment in recurrent or metastatic head and neck cancer. Br J Cancer 94:631-636
15. Kroon BK, Horenblas S, Lont AP et al (2005) Patients with penile carcinoma benefit from immediate resection of clinically occult lymph node metastases. J Urol 173:816-819
16. Lee CS, Redshaw A, Boag G (1997) Epidermal growth factor receptor immunoreactivity in human laryngeal squamous cell carcinoma. Pathology 29:251-254
17. Mistry T, Jones RWA, Dannatt E et al (2007) A 10-year retrospective audit of penile cancer management in the UK. BJU Int 100:1277-1281
18. M?ller-Tidow C, Krug U, Brunnberg U et al (2007) Tyrosinkinasen als Ziele neuer onkologischer Therapien. Dtsch ?rztebl 19:1165-1172
19. Perez-Soler R (2004) HER1/EGFR targeting: refining the strategy. Oncologist 9:58-67
20. Pizzocaro G, Piva L (1988) Adjuvant and neoadjuvant vincristine, bleomycin, and methotrexate for inguinal metastases from squamous cell carcinoma of the penis. Acta Oncol 27:823-824
21. Pizzocaro G, Piva L, Bandieramonte G, Tana S (1997) Up-to-date management of carcinoma of the penis. Eur Urol 32:5-15
22. Pizzocaro G, Nicolai N, Milani A (2009) Taxanes in combination with cisplatin and fluorouracil for advanced penile cancer: preliminary results. Eur Urol 55:546-551
23. Preis E, Albers P, Jakse G (2006) Systemtherapie des Peniskarzinoms. Urologe A 45:609-613
24. Protzel C, Hakenberg OW (2009) Chemotherapy in patients with penile carcinoma Urol Int 82:1-7
25. Ravi R (1993) Correlation between the extent of nodal involvement and survival following groin dissection for carcinoma of the penis. Br J Urol 72:817-819
26. Soulieres D, Senzer NN, Vokes EE et al (2004) Multicenter phase II study of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent or metastatic squamous cell cancer of the head and neck. J Clin Oncol 22:77-85
27. Srinivas V, Morse MJ, Herr HW et al (1987) Penile cancer: Relation of extent of nodal metastasis to survival. J Urol 137:880-882
28. Stewart JSW, Cohen EE, Licitra L et al (2007) A phase III randomized parallel-group study of gefitinib (IRESSA) versus methotrexate (IMEX) in patients with recurrent squamous cell carcinoma of the head and neck. American Association for Cancer Research Annual Meeting: Proceedings, Los Angeles, CA
29. Vermorken J, Mesia R, Vega V et al (2007) Cetuximab extends survival of patients with recurrent or metastasis SCCHN when added to first line platinum based therapy - results of a randomised phase III (Extreme) study. J Clin Oncol Proc Am Soc Clin Oncol 25:6091
30. Vermorken JB, Trigo J, Hitt R et al (2007) Open-label, uncontrolled, multicenter phase II study to evaluate the efficacy and toxicity of cetuximab as a single agent in patients with recurrent and /or metastatic squamous cell carcinoma of the head and neck who failed to respond to platinum-based therapy. J Clin Oncol 25:2171-2177